Last reviewed · How we verify
BROMEBRIC ACID
BROMEBRIC ACID is a bromebric acid drug. It is currently in Phase 2 development.
Bromebic acid is thought to work by inhibiting a specific enzyme or receptor, but the exact mechanism is unknown.
Bromebic acid is a small molecule drug of the bromebric acid class, but its details are limited. Its original developer and current owner are unknown. The target and approved indications of bromebic acid are also not specified. Its commercial status, including whether it is patented or generic, and key safety considerations are not available. Further research is needed to understand its pharmacological properties and clinical applications.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BROMEBRIC ACID |
|---|---|
| Drug class | bromebric acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and enzymes are like keys that unlock them. Bromebic acid is like a special key that blocks the enzyme from working properly, which can help treat certain conditions. However, the exact way it works is still a mystery.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BROMEBRIC ACID CI brief — competitive landscape report
- BROMEBRIC ACID updates RSS · CI watch RSS
Frequently asked questions about BROMEBRIC ACID
What is BROMEBRIC ACID?
How does BROMEBRIC ACID work?
What drug class is BROMEBRIC ACID in?
What development phase is BROMEBRIC ACID in?
Related
- Drug class: All bromebric acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing